CORDIS · 115439 · FP7
STEMBANCC Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)
Coordinator: F. HOFFMANN-LA ROCHE AG (CH)
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a wealth of clinical data. Furthermore our cohorts include genetic and genome data, allowing us to carefully select subjects for hiPSC based disease model development. This clinical-genetic stratificatio…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €26.0M toward a total project budget of €55.0M — a funding rate of 47%, with the remainder covered by the consortium partners. The project runs over approximately 5.5 years from 2012-10-01 to 2018-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
- EU-AIMS — European Autism Interventions - A Multicentre Study for Developing New Medications115300 · FP7 · €20.5M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €26.0M toward a total project budget of €55.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by F. HOFFMANN-LA ROCHE AG (CH).
- What is the project timeline?
- The project runs from 2012-10-01 to 2018-03-31 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115439.